Segment 11: High Cost Trends Trickling Into Other Disease Areas

Although the marketplace has managed to come to a temporary solution for the high cost of hepatitis C drugs, Steven Miller, MD, MBA, expects to see more examples of similar high-cost drugs in other categories.

In particular he highlighted PCSK9 inhibitors for high cholesterol coming to the marketplace and the explosion of spectacular oncology products.

“I think we’re entering a new era where we have an unsustainable situation,” he said.